NO2017023I2 - Venetoklaks - Google Patents

Venetoklaks

Info

Publication number
NO2017023I2
NO2017023I2 NO2017023C NO2017023C NO2017023I2 NO 2017023 I2 NO2017023 I2 NO 2017023I2 NO 2017023 C NO2017023 C NO 2017023C NO 2017023 C NO2017023 C NO 2017023C NO 2017023 I2 NO2017023 I2 NO 2017023I2
Authority
NO
Norway
Prior art keywords
venetoklaks
Prior art date
Application number
NO2017023C
Other languages
English (en)
Other versions
NO2017023I1 (no
Original Assignee
Abbvie Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42677657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017023(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Ireland Unlimited Co filed Critical Abbvie Ireland Unlimited Co
Publication of NO2017023I1 publication Critical patent/NO2017023I1/no
Publication of NO2017023I2 publication Critical patent/NO2017023I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
NO2017023C 2009-05-26 2017-05-29 Venetoklaks NO2017023I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18120309P 2009-05-26 2009-05-26
PCT/US2010/036198 WO2010138588A2 (en) 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Publications (2)

Publication Number Publication Date
NO2017023I1 NO2017023I1 (no) 2017-05-29
NO2017023I2 true NO2017023I2 (no) 2017-05-29

Family

ID=42677657

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2017023C NO2017023I2 (no) 2009-05-26 2017-05-29 Venetoklaks

Country Status (43)

Country Link
US (1) US8580794B2 (no)
EP (3) EP2435432B3 (no)
JP (7) JP5747025B2 (no)
KR (8) KR20190086591A (no)
CN (5) CN109897038B (no)
AR (2) AR076705A1 (no)
AU (1) AU2010254160C1 (no)
BR (2) BR122019016429B1 (no)
CA (4) CA2929347A1 (no)
CL (1) CL2011002949A1 (no)
CO (1) CO6480950A2 (no)
CR (2) CR20170019A (no)
CY (2) CY1117423T1 (no)
DK (1) DK2435432T6 (no)
DO (1) DOP2011000367A (no)
EC (1) ECSP11011554A (no)
ES (1) ES2546294T7 (no)
FI (1) FI2435432T6 (no)
HK (2) HK1163099A1 (no)
HR (1) HRP20151001T4 (no)
HU (2) HUE027698T2 (no)
IL (5) IL299019A (no)
LT (1) LTC2435432I2 (no)
ME (1) ME02205B (no)
MX (2) MX339469B (no)
MY (1) MY155645A (no)
NL (1) NL300873I2 (no)
NO (1) NO2017023I2 (no)
NZ (1) NZ595708A (no)
PE (1) PE20120345A1 (no)
PH (1) PH12015500297A1 (no)
PL (1) PL2435432T6 (no)
PT (1) PT2435432E (no)
RS (1) RS54234B2 (no)
RU (3) RU2573832C2 (no)
SG (2) SG10201704742YA (no)
SI (1) SI2435432T2 (no)
SM (1) SMT201500225B (no)
TW (3) TWI476195B (no)
UA (1) UA106079C2 (no)
UY (3) UY32668A (no)
WO (1) WO2010138588A2 (no)
ZA (1) ZA201108616B (no)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SI2376480T1 (sl) * 2008-12-05 2016-10-28 Abbvie Inc. Sulfonamidni derivati kot Bcl-2-selektivna apoptozo inducirajoča sredstva za zdravljenje raka in imunskih bolezni
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
JP5613176B2 (ja) * 2009-01-19 2014-10-22 アッヴィ・インコーポレイテッド 癌並びに免疫及び自己免疫疾患の治療用アポトーシス誘導剤
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20190086591A (ko) * 2009-05-26 2019-07-22 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
MY191929A (en) 2010-06-03 2022-07-18 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
KR102095698B1 (ko) * 2010-10-29 2020-04-01 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2643322B1 (en) * 2010-11-23 2017-08-30 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
HUE031267T2 (en) 2010-11-23 2017-06-28 Abbvie Ireland Unlimited Co Methods of treatment using selective BCL-2 inhibitors
US9108910B2 (en) 2011-02-15 2015-08-18 Ube Industries, Ltd. Industrial methods for producing arylsulfur pentafluorides
CN102241649A (zh) * 2011-07-08 2011-11-16 陈飞 3-四氢呋喃甲醇的制备方法
CN103958508B (zh) 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
WO2013185202A1 (en) * 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US8883784B2 (en) * 2012-08-13 2014-11-11 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN111481552A (zh) 2012-09-07 2020-08-04 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
TR201812261T4 (tr) * 2012-11-01 2018-11-21 Infinity Pharmaceuticals Inc Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
AR095265A1 (es) 2013-03-13 2015-09-30 Abbvie Inc Procesos para la preparación de un agente inductor de la apoptosis
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014168975A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
WO2015171591A1 (en) 2014-05-05 2015-11-12 Board Of Trustees Of The University Of Arkansas COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
CA2955972A1 (en) 2014-07-22 2016-01-28 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
CN104163798A (zh) * 2014-07-29 2014-11-26 苏州康润医药有限公司 3-氨基-8-三氟甲基喹啉的合成方法
EP3179991B1 (en) 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
HUE051972T2 (hu) 2014-10-06 2021-04-28 Vertex Pharma Cisztás fibrózis transzmembrán konduktancia regulátor modulátorai
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
RS58823B1 (sr) 2015-07-07 2019-07-31 Hoffmann La Roche Kombinovana terapija konjugatom anti-her2 antitelo-lek i bcl-2 inhibitorom
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
CN108367006B (zh) 2015-12-04 2021-12-31 博尔托拉制药公司 用于治疗血液癌症的赛度替尼
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
MY197785A (en) 2016-03-15 2023-07-13 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
BR112018068565A2 (pt) 2016-03-15 2019-02-12 Oryzon Genomics, S.A. combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
KR102447884B1 (ko) * 2016-04-21 2022-09-27 바이오벤처스, 엘엘씨 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
WO2018027097A1 (en) 2016-08-05 2018-02-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
WO2018041248A1 (zh) * 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
BR112019006213A2 (pt) 2016-09-30 2019-06-18 Vertex Pharma modulador de regulador de condutância transmembranar de fibrose cística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
PE20241131A1 (es) 2016-12-09 2024-05-24 Vertex Pharma Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
CN110177788B (zh) * 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
WO2018167652A1 (en) * 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
EP4119560B1 (en) 2017-04-18 2024-06-05 Fochon Pharmaceuticals, Ltd. Apoptosis-inducing agents
CN107089981A (zh) * 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019001383A1 (zh) 2017-06-26 2019-01-03 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019020610A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY USING BET INHIBITOR AND BCL-2 INHIBITOR
JP2020528061A (ja) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
WO2019028228A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS
EP3672975B1 (en) 2017-08-23 2023-04-12 Guangzhou Lupeng Pharmaceutical Company Ltd. Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
CN111801327B (zh) 2018-01-10 2024-02-09 里科瑞尔姆Ip控股有限责任公司 苯甲酰胺化合物
EP3743069A4 (en) 2018-01-22 2021-06-09 BioVentures, LLC DEGRADER OF BCL-2 PROTEIN FOR CANCER TREATMENT
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US20190336496A1 (en) 2018-02-16 2019-11-07 Abbvie Inc. Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
CN114369094B (zh) * 2018-03-30 2023-09-29 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CA3098348A1 (en) * 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 inhibitors
EP3788035A2 (en) 2018-05-04 2021-03-10 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
TW202023568A (zh) 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
CA3092753C (en) 2018-07-31 2023-10-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab
EP3672595B1 (en) 2018-07-31 2021-07-21 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN114522167A (zh) 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
UA126098C2 (uk) 2018-07-31 2022-08-10 Есентейдж Фарма (Сучжоу) Ко., Лтд. КОМБІНОВАНИЙ ПРОДУКТ НА ОСНОВІ ІНГІБІТОРА Bcl-2 ТА ІНГІБІТОРА MDM2 ТА ЙОГО ЗАСТОСУВАННЯ В ПОПЕРЕДЖЕННІ ТА/АБО ЛІКУВАННІ ЗАХВОРЮВАНЬ
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
CN116199686A (zh) 2018-10-29 2023-06-02 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物
CN109320516A (zh) * 2018-11-30 2019-02-12 重庆三圣实业股份有限公司 一种维奈妥拉中间体的制备方法及其产品
CN109438441A (zh) * 2018-11-30 2019-03-08 重庆三圣实业股份有限公司 一种维奈妥拉的制备方法及其产品
WO2020232214A1 (en) 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
EP3978494A4 (en) * 2019-05-24 2023-04-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. METHYL AND TRFLUOROMETHYL CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITORS
WO2021037933A1 (en) 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
CN112661751B (zh) * 2019-10-16 2024-06-14 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
EP4051676A4 (en) * 2019-10-28 2023-11-22 BeiGene, Ltd. BCL-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
CN115397825A (zh) * 2020-04-29 2022-11-25 正大天晴药业集团股份有限公司 三氟甲基和氯双取代的磺酰胺类选择性bcl-2抑制剂的晶体
CN111848607B (zh) * 2020-07-22 2023-03-17 长沙创新药物工业技术研究院有限公司 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
WO2022037683A1 (en) * 2020-08-21 2022-02-24 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2022089463A1 (zh) * 2020-10-28 2022-05-05 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
CN114736203A (zh) * 2021-01-07 2022-07-12 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CA3211639A1 (en) 2021-03-19 2022-09-22 Volodymyr KYSIL Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors
WO2022218311A1 (en) * 2021-04-13 2022-10-20 Appicine Therapeutics (Hk) Limited Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof
EP4353722A1 (en) 2021-06-04 2024-04-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phosphate of trifluoromethyl-substituted sulfonamide compound
EP4396180A1 (en) * 2021-08-31 2024-07-10 BeiGene, Ltd. Solid forms of bcl-2 inhibitors, method of preparation, and use thereof
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
WO2023107606A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2024012557A1 (en) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
WO2024017354A1 (en) * 2022-07-21 2024-01-25 Beigene, Ltd. Methods of treating multiple myeloma using bcl-2 inhibitor
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
KR102598137B1 (ko) 2022-11-24 2023-11-06 율촌화학 주식회사 고차단성 생분해 필름 및 이의 제조방법

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
CA2016710A1 (en) * 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB9110625D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
BR9307570A (pt) * 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
AU732406B2 (en) * 1997-10-03 2001-04-26 Merck Frosst Canada & Co. Aryl thiophene derivatives as PDE IV inhibitors
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
AU767456B2 (en) * 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
DE19830430A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
KR100641802B1 (ko) * 1999-12-28 2006-11-02 에자이 가부시키가이샤 술폰아미드 함유 복소환 화합물
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2446719A1 (en) 2001-06-06 2002-12-12 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
US20030059489A1 (en) 2001-09-24 2003-03-27 Canolio Inc. Genital lubricating compositions and uses thereof
WO2003026587A2 (en) * 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US6995787B2 (en) 2002-08-21 2006-02-07 Adams Steven L Sports projectile and camera apparatus
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
NZ552183A (en) * 2004-06-17 2009-10-30 Infinity Discovery Inc Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
PT1888550E (pt) * 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
BRPI0610828A2 (pt) 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20070115787A1 (en) * 2005-11-23 2007-05-24 Seagate Technology Llc Planar optical device for generating optical nanojets
CN101534904B (zh) * 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8557983B2 (en) * 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) * 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
SI2376480T1 (sl) 2008-12-05 2016-10-28 Abbvie Inc. Sulfonamidni derivati kot Bcl-2-selektivna apoptozo inducirajoča sredstva za zdravljenje raka in imunskih bolezni
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
JP5613176B2 (ja) * 2009-01-19 2014-10-22 アッヴィ・インコーポレイテッド 癌並びに免疫及び自己免疫疾患の治療用アポトーシス誘導剤
MX2011007684A (es) * 2009-01-19 2011-08-08 Abbott Lab Agentes inductores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
KR20190086591A (ko) 2009-05-26 2019-07-22 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Also Published As

Publication number Publication date
LTPA2017015I1 (lt) 2017-06-12
CN102448959A (zh) 2012-05-09
CY1117423T1 (el) 2017-04-26
DOP2011000367A (es) 2017-07-31
TWI537269B (zh) 2016-06-11
UY37825A (es) 2020-02-28
RU2535347C3 (ru) 2019-05-14
SMT201500225B (it) 2015-10-30
CO6480950A2 (es) 2012-07-16
KR102001418B1 (ko) 2019-07-19
CN102448959B (zh) 2015-06-17
KR101659583B1 (ko) 2016-09-29
NZ595708A (en) 2014-03-28
ES2546294T7 (es) 2024-06-06
ES2546294T3 (es) 2015-09-22
TW201506025A (zh) 2015-02-16
RU2535347C2 (ru) 2014-12-10
EP2944638A1 (en) 2015-11-18
AR076705A1 (es) 2011-06-29
IL269092A (en) 2019-11-28
JP2017048219A (ja) 2017-03-09
CA2759182A1 (en) 2010-12-02
US20110124628A1 (en) 2011-05-26
JP2015110605A (ja) 2015-06-18
CA3052016A1 (en) 2010-12-02
KR20180049164A (ko) 2018-05-10
EP2435432A2 (en) 2012-04-04
RU2014132884A (ru) 2015-12-27
TWI476195B (zh) 2015-03-11
SI2435432T2 (sl) 2024-04-30
KR20180124164A (ko) 2018-11-20
CN109897038B (zh) 2022-04-05
SI2435432T1 (sl) 2015-10-30
NO2017023I1 (no) 2017-05-29
UY32668A (es) 2010-12-31
ZA201108616B (en) 2015-12-23
CL2011002949A1 (es) 2012-05-25
HK1215576A1 (zh) 2016-09-02
AU2010254160A1 (en) 2011-11-24
SG10201704742YA (en) 2017-07-28
JP6353506B2 (ja) 2018-07-04
SG175253A1 (en) 2011-11-28
KR20190130676A (ko) 2019-11-22
HRP20151001T4 (hr) 2024-02-16
CN109897038A (zh) 2019-06-18
BRPI1014359B1 (pt) 2019-11-05
US8580794B2 (en) 2013-11-12
JP2023040165A (ja) 2023-03-22
PH12015500297A1 (en) 2015-12-07
KR20120034671A (ko) 2012-04-12
AU2010254160C1 (en) 2023-07-06
MX2019012154A (es) 2019-11-21
WO2010138588A9 (en) 2011-05-05
CN104906100A (zh) 2015-09-16
RS54234B2 (sr) 2024-02-29
HRP20151001T1 (hr) 2015-10-23
DK2435432T3 (en) 2015-08-31
IL215644A (en) 2017-08-31
CN104876927B (zh) 2017-06-23
HUE027698T2 (en) 2016-10-28
JP2022033939A (ja) 2022-03-02
CA2759182C (en) 2016-06-07
CN109966294A (zh) 2019-07-05
EP2435432B1 (en) 2015-06-24
ECSP11011554A (es) 2012-01-31
CR20170019A (es) 2017-05-12
KR101723378B1 (ko) 2017-04-06
IL286036A (en) 2021-10-31
BRPI1014359A2 (pt) 2016-04-05
AU2010254160B2 (en) 2015-02-12
CY2017019I1 (el) 2018-01-10
RU2011152973A (ru) 2013-07-10
KR20190086591A (ko) 2019-07-22
WO2010138588A3 (en) 2011-04-07
MX2011012257A (es) 2011-12-16
KR20150065947A (ko) 2015-06-15
PL2435432T3 (pl) 2015-12-31
TWI561523B (en) 2016-12-11
KR101920202B1 (ko) 2018-11-21
JP5747025B2 (ja) 2015-07-08
RU2628885C2 (ru) 2017-08-22
AR109974A2 (es) 2019-02-13
PE20120345A1 (es) 2012-05-17
CN104876927A (zh) 2015-09-02
JP2018138577A (ja) 2018-09-06
RU2015154494A (ru) 2017-06-22
HUS1700021I1 (hu) 2017-06-28
JP2020023545A (ja) 2020-02-13
DK2435432T6 (da) 2023-12-18
IL215644A0 (en) 2012-01-31
JP6038195B2 (ja) 2016-12-07
LTC2435432I2 (lt) 2018-06-11
CA3206963A1 (en) 2010-12-02
JP2012528178A (ja) 2012-11-12
RS54234B1 (en) 2015-12-31
UY33047A (es) 2011-09-30
MY155645A (en) 2015-11-13
KR20230128571A (ko) 2023-09-05
KR20170037683A (ko) 2017-04-04
PL2435432T6 (pl) 2024-02-12
MX339469B (es) 2016-05-27
CY2017019I2 (el) 2018-01-10
CA2929347A1 (en) 2010-12-02
FI2435432T6 (fi) 2023-11-21
TW201107323A (en) 2011-03-01
BR122019016429B1 (pt) 2020-03-24
EP2435432B3 (en) 2023-10-25
TW201607946A (zh) 2016-03-01
RU2573832C2 (ru) 2016-01-27
NL300873I2 (nl) 2017-10-24
IL253891A0 (en) 2017-10-31
WO2010138588A2 (en) 2010-12-02
UA106079C2 (uk) 2014-07-25
CR20110632A (es) 2012-02-15
HK1163099A1 (en) 2012-09-07
ME02205B (me) 2016-02-20
PT2435432E (pt) 2015-10-13
IL299019A (en) 2023-02-01
EP3656771A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
NO2017023I2 (no) Venetoklaks
DK2414015T3 (da) Laryngoskopsystem
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
DK2411442T4 (da) Umættet polyesterresin
DK2430035T3 (da) Uracylspipooxetannukleosider
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112010004249A5 (de) Spindelaktor
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
DK2483126T3 (da) Skinnekøretøj
DK2506968T3 (da) Faujasit-zeolit
DE112010004865T8 (de) Lamellennassreibkupplung
DE112010003255A5 (de) Fördergutverteiler
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
FI20090100A0 (fi) Biotinidaasimääritys
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
DE112010002351A5 (de) Klemmorrichtung
DE112010003843T8 (de) Lastansteuervorrichtung
DE202009005065U8 (de) Kartonverschließmaschine
DE102009034429A8 (de) Flachantenne
DE112010004370A5 (de) Solarkollektorsystern

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE IRELAND UNLIMITED COMPANY, BM